Melanoma & Skin Cancer | Specialty

Dr. Kiran Turaga on Regional Therapies in Melanoma

October 7th 2016

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses regional therapies in melanoma.

Dr. Kaufman on T-VEC in Melanoma

October 7th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.

Dr. Weber on Selecting Immunotherapy for Patients With Melanoma

October 5th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses considering factors when selecting an immunotherapy agent for a patient with melanoma.

Encorafenib/Binimetinib Combo Improves PFS Versus Vemurafenib in Phase III Melanoma Study

September 26th 2016

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved progression-free survival compared with single-agent vemurafenib for patients with BRAF-mutant melanoma.

Dr. Saenger on Ongoing Research in Melanoma

September 21st 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses ongoing research related to immunotherapy in the field of melanoma. Sanger shared this insight during an interview with OncLive during the recent Society for Immunotherapy of Cancer Cancer Immunotherapy 101 meeting in New York City.

Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in Melanoma

September 21st 2016

Dr. Dummer on Driver Mutations and Next Steps in Melanoma

September 15th 2016

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.

Dr. Wolchok on the Safety Profile in CheckMate-067 in Melanoma

September 15th 2016

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, discusses the safety profile in the CheckMate-067 trial, which examined nivolumab combined with ipilimumab in treatment-naïve patients with advanced melanoma.

Dr. D'Orazio on UV Signature Mutations in Melanoma

September 9th 2016

John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

A Closer Look at BRAF Melanoma Testing Reveals Intricacies of V600 Mutation

September 5th 2016

BRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma. Activating mutations of BRAF are present in 40% to 60% of all melanoma cases, with more than 90% of mutations found at codon 600 in exon 15.

Expert Discusses Next Steps With Immunotherapy in Melanoma

September 2nd 2016

Yvonee Saenger, MD, discusses ongoing developments with immunotherapy in melanoma.

FDA Accepts Binimetinib NDA for NRAS-Mutant Melanoma

September 1st 2016

The FDA has assigned a standard review designation to a new drug application for binimetinib as a treatment for patients with NRAS-mutant advanced melanoma.

Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma

August 25th 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Dr. Keith T. Flaherty on the NEMO Trial in NRAS-Mutant Melanoma

August 23rd 2016

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Treatment Options for Melanoma Outpace Data on How to Use Them

August 16th 2016

With several more melanoma treatments poised to emerge from the pipeline, data on the optimal way to incorporate these novel drugs into practice lag far behind the breakneck pace of approvals.

Immunotherapy Transforms Melanoma Care, But Challenges Remain

August 12th 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Dr. Reinhard Dummer on Toxicities with Binimetinib in Metastatic Melanoma

August 11th 2016

Final OS Analysis Confirms Cobimetinib/Vemurafenib Benefit in Melanoma

August 10th 2016

Combination therapy with cobimetinib (Cotellic) and vemurafenib (Zelboraf) reduced the risk of death by 30% compared with vemurafenib alone in patients with BRAF-positive advanced melanoma.